Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.42 |
| ▸ | HTR2A | P28223 | 15/20 | 0.42 |
| ▸ | HTR2B | P41595 | 10/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6320155 | 0.82 | ITGB3 (0.49) | HTR2CHTR2AHTR2B | |
| SCHEMBL6319144 | 0.78 | KDM1A (0.36) | HTR2CHTR2AHTR2BKCNH2 | |
| SCHEMBL6319899 | 0.74 | PDE4A (0.47) | — | |
| SCHEMBL28037017 | 0.73 | KDM1A (0.56) | HTR2CHTR2AHTR2BKCNH2 | |
| SCHEMBL15669104 | 0.70 | KDM1A (0.50) | HTR2CHTR2AHTR2B | |
| SCHEMBL2545568 | 0.69 | USP30 (0.37) | HTR2AHTR2B | |
| SCHEMBL2545570 | 0.69 | USP30 (0.37) | HTR2AHTR2B | |
| SCHEMBL6251810 | 0.68 | HTR2C (0.61) | HTR2CHTR2AHTR2B | |
| SCHEMBL2540282 | 0.68 | USP30 (0.35) | HTR2C | |
| SCHEMBL2540281 | 0.68 | USP30 (0.35) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | HTR2C 2450/4885HTR2A 2084/4885HTR2B 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.